Myriam Khalili1, Fanny Lepeytre1, Jason Robert Guertin1, Rémi Goupil1, Stéphan Troyanov1, Josée Bouchard1, François Madore2. 1. Faculty of Medicine (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Université de Montréal; Centre de recherche de l'Hôpital du Sacré-Coeur de Montréal (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Montréal, Que.; Département de médecine sociale et preventive (Guertin), Faculty of Medicine, Université Laval; Centre de recherche du Centre hospitalier universitaire de Québec (Guertin), Québec, Que. 2. Faculty of Medicine (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Université de Montréal; Centre de recherche de l'Hôpital du Sacré-Coeur de Montréal (Khalili, Lepeytre, Goupil, Troyanov, Bouchard, Madore), Montréal, Que.; Département de médecine sociale et preventive (Guertin), Faculty of Medicine, Université Laval; Centre de recherche du Centre hospitalier universitaire de Québec (Guertin), Québec, Que. f.madore@umontreal.ca.
Abstract
BACKGROUND: The debate over acetylsalicylic acid (ASA) therapy for primary prevention of cardiovascular disease (CVD) has recently resurfaced, but scarce data are available on prophylactic ASA use in Canada for this purpose. This study aimed to evaluate the prevalence and factors associated with ASA use, and the potential impact of implementing the most recent (2016) US Preventive Services Task Force recommendations for primary CVD prevention in a Canadian setting. METHODS: We performed a cross-sectional analysis using data from the CARTaGENE study, which included a representative sample (n = 20 004) of the 2018 general population of the province of Quebec. We assessed eligibility for ASA treatment using US Preventive Services Task Force criteria (age 50-69 yr, no past history of myocardial infarction or stroke, and 10-year risk of CVD of at least 10%). We extrapolated to the entire 2018 Quebec population the number of people who would need to start ASA treatment. RESULTS: A total of 6231 respondents in the CARTaGENE study (54.2% of those aged 50-69 yr with no prior history of CVD) were found to be potentially eligible for ASA use for primary CVD prevention. Of the 6231, 1379 (22.1%) were receiving prophylactic ASA treatment. Factors found to be related to ASA use included age, male sex, regular medical visits, lower education level, obesity, hypertension, diabetes and dyslipidemia. Income and smoking status were not found to be significantly associated with ASA use. Our results indicate that 885 261 people would potentially have started ASA treatment if the US Preventive Services Task Force recommendations had been implemented in Quebec in 2018. INTERPRETATION: Prevalent ASA use for primary CVD prevention was low. Implementation of the 2016 US Preventive Services Task Force recommendations would require initiating ASA treatment in a substantial proportion of people, with undetermined potential benefits. Copyright 2020, Joule Inc. or its licensors.
BACKGROUND: The debate over acetylsalicylic acid (ASA) therapy for primary prevention of cardiovascular disease (CVD) has recently resurfaced, but scarce data are available on prophylactic ASA use in Canada for this purpose. This study aimed to evaluate the prevalence and factors associated with ASA use, and the potential impact of implementing the most recent (2016) US Preventive Services Task Force recommendations for primary CVD prevention in a Canadian setting. METHODS: We performed a cross-sectional analysis using data from the CARTaGENE study, which included a representative sample (n = 20 004) of the 2018 general population of the province of Quebec. We assessed eligibility for ASA treatment using US Preventive Services Task Force criteria (age 50-69 yr, no past history of myocardial infarction or stroke, and 10-year risk of CVD of at least 10%). We extrapolated to the entire 2018 Quebec population the number of people who would need to start ASA treatment. RESULTS: A total of 6231 respondents in the CARTaGENE study (54.2% of those aged 50-69 yr with no prior history of CVD) were found to be potentially eligible for ASA use for primary CVD prevention. Of the 6231, 1379 (22.1%) were receiving prophylactic ASA treatment. Factors found to be related to ASA use included age, male sex, regular medical visits, lower education level, obesity, hypertension, diabetes and dyslipidemia. Income and smoking status were not found to be significantly associated with ASA use. Our results indicate that 885 261 people would potentially have started ASA treatment if the US Preventive Services Task Force recommendations had been implemented in Quebec in 2018. INTERPRETATION: Prevalent ASA use for primary CVD prevention was low. Implementation of the 2016 US Preventive Services Task Force recommendations would require initiating ASA treatment in a substantial proportion of people, with undetermined potential benefits. Copyright 2020, Joule Inc. or its licensors.
Authors: Kara A Nerenberg; Kelly B Zarnke; Alexander A Leung; Kaberi Dasgupta; Sonia Butalia; Kerry McBrien; Kevin C Harris; Meranda Nakhla; Lyne Cloutier; Mark Gelfer; Maxime Lamarre-Cliche; Alain Milot; Peter Bolli; Guy Tremblay; Donna McLean; Raj S Padwal; Karen C Tran; Steven Grover; Simon W Rabkin; Gordon W Moe; Jonathan G Howlett; Patrice Lindsay; Michael D Hill; Mike Sharma; Thalia Field; Theodore H Wein; Ashkan Shoamanesh; George K Dresser; Pavel Hamet; Robert J Herman; Ellen Burgess; Steven E Gryn; Jean C Grégoire; Richard Lewanczuk; Luc Poirier; Tavis S Campbell; Ross D Feldman; Kim L Lavoie; Ross T Tsuyuki; George Honos; Ally P H Prebtani; Gregory Kline; Ernesto L Schiffrin; Andrew Don-Wauchope; Sheldon W Tobe; Richard E Gilbert; Lawrence A Leiter; Charlotte Jones; Vincent Woo; Robert A Hegele; Peter Selby; Andrew Pipe; Philip A McFarlane; Paul Oh; Milan Gupta; Simon L Bacon; Janusz Kaczorowski; Luc Trudeau; Norman R C Campbell; Swapnil Hiremath; Michael Roerecke; Joanne Arcand; Marcel Ruzicka; G V Ramesh Prasad; Michel Vallée; Cedric Edwards; Praveena Sivapalan; S Brian Penner; Anne Fournier; Geneviève Benoit; Janusz Feber; Janis Dionne; Laura A Magee; Alexander G Logan; Anne-Marie Côté; Evelyne Rey; Tabassum Firoz; Laura M Kuyper; Jonathan Y Gabor; Raymond R Townsend; Doreen M Rabi; Stella S Daskalopoulou Journal: Can J Cardiol Date: 2018-03-01 Impact factor: 5.223
Authors: Michael Pignone; George K Anderson; Katherine Binns; Hugh H Tilson; Steven M Weisman Journal: Am J Prev Med Date: 2007-05 Impact factor: 5.043
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Nicolas Rodondi; Jacques Cornuz; Pedro Marques-Vidal; Javed Butler; Daniel Hayoz; Alain Pécoud; Fred Paccaud; Gérard Waeber; Peter Vollenweider Journal: Prev Med Date: 2007-08-23 Impact factor: 4.018
Authors: Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno Journal: Eur Heart J Date: 2016-05-23 Impact factor: 29.983
Authors: Sreenivasa Rao Kondapally Seshasai; Shanelle Wijesuriya; Rupa Sivakumaran; Sarah Nethercott; Sebhat Erqou; Naveed Sattar; Kausik K Ray Journal: Arch Intern Med Date: 2012-01-09